BRAF and MEK inhibitors rechallenge after an adverse drug reaction in patients with cancer: A pharmacovigilance cohort study
In real-world settings, approximately two-fifths of cases with notified TT rechallenges led to a reporting of recurrence of the same initial ADR. The primary determinant of reported recurrence seems to be the nature of the initial ADR rather than the TT regimen, or any other baseline patient characteristic.
Authors
- Basile Chrétien (ORCID: https://orcid.org/0000-0002-7483-2489)
- Joachim Alexandre
- Célèste Lebbé (ORCID: https://orcid.org/0000-0002-5854-7290)
- S. Idoudi (ORCID: https://orcid.org/0000-0001-6285-5176)
- Angélique Da Silva (ORCID: https://orcid.org/0000-0002-8193-5144)
- Marion Sassier
- Charles Dolladille (ORCID: https://orcid.org/0000-0003-0449-6261)
- Emilien Ezine (ORCID: https://orcid.org/0000-0001-5869-1914)
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Saint Louis University Hospital (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Hôpital Saint-Louis (FR)
- Nagoya University (JP)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- Therapies
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1016/j.therap.2024.12.011
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00